Hana Biosciences (AMEX:HBX), a South San Francisco-based biopharmaceutical company focused on advancing cancer care, announced today positive interim data from an ongoing, multi-center Phase I clinical study evaluating single agent Talotrexin (PT-523) in relapsed or refractory advanced non-small cell lung cancer (NSCLC). The Talotrexin in Lung Cancer (TLC-1) study will be presented at the American Association for Cancer Research-National Cancer Institute-European Organisation for Research and Treatment of Cancer (AACR-NCI-EORTC) International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia, Pennsylvania, on November 16, 2005.
